Neoadjuvant Chemotherapy Induces Expression Levels of Breast Cancer Resistance Protein That Predict Disease-Free Survival in Breast Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kim, Baek ^a,b   Fatayer, Hiba ^b   Hanby, Andrew M ^c   Horgan, Kieran ^b   Perry, Sarah L ^a   Valleley, Elizabeth M A ^a   Verghese, Eldo T ^c   Williams, Bethany J ^c   Thorne, James L ^a   Hughes, Thomas A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE; UPREGULATION;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; UP-REGULATION;

EID: 84877043382     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062766     Document Type: Article

References (33)

1. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE, (2012) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 15: 50-61.
2. Leonard GD, Fojo T, Bates SE, (2003) The role of ABC transporters in clinical practice. The oncologist 8: 411-424.
3. Rivera E, (2010) Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. The breast journal 16: 252-263.
4. Leonessa F, Clarke R, (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocrine-related cancer 10: 43-73.
5. Tsukamoto F, Shiba E, Taguchi T, Sugimoto T, Watanabe T, et al. (1997) Immunohistochemical Detection of P-glycoprotein in Breast Cancer and Its Significance as a Prognostic Factor. Breast cancer 4: 259-263.
6. Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, et al. (2004) Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. International journal of cancer Journal international du cancer 112: 286-294.
7. Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, et al. (2003) Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast cancer research and treatment 81: 149-157.
8. Fletcher JI, Haber M, Henderson MJ, Norris MD, (2010) ABC transporters in cancer: more than just drug efflux pumps. Nature reviews Cancer 10: 147-156.
9. Doyle LA, Ross DD, (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358.
10. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9: 827-836.
11. Mo W, Zhang JT, (2012) Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3: 1-27.
12. Tamura A, Wakabayashi K, Onishi Y, Takeda M, Ikegami Y, et al. (2007) Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98: 231-239.
13. Nakanishi T, Ross DD, (2012) Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chinese journal of cancer 31: 73-99.
14. Xiang L, Su P, Xia S, Liu Z, Wang Y, et al. (2011) ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn Pathol 6: 90.
15. Mieog JS, van der Hage JA, van de Velde CJ, (2007) Neoadjuvant chemotherapy for operable breast cancer. The British journal of surgery 94: 1189-1200.
16. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, et al. (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Annals of surgical oncology 19: 1508-1516.
17. Marinovich ML, Sardanelli F, Ciatto S, Mamounas E, Brennan M, et al. (2012) Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI. Breast 21: 669-677.
18. Hanrahan EO, Hennessy BT, Valero V, (2005) Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert opinion on pharmacotherapy 6: 1477-1491.
19. Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, et al. (2012) Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer. British journal of cancer.
20. Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, et al. (2012) CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer. PloS one 7: e45865.
21. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, et al. (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clinical cancer research: an official journal of the American Association for Cancer Research 4: 389-398.
22. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, et al. (1996) MRP and MDR1 gene expression in primary breast carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research 2: 1231-1237.
23. Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim SJ, et al. (2011) Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 37: 155-161.
24. Mechetner EB, Roninson IB, (1992) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America 89: 5824-5828.
25. Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, et al. (2006) Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Molecular pharmacology 69: 1499-1505.
26. van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, et al. (2012) Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast cancer research and treatment 133: 49-59.
27. Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, et al. (2010) Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 2198-2206.
28. Chintamani, Singh JP, Mittal MK, Saxena S, Bansal A, et al. (2005) Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study. World journal of surgical oncology 3: 61.
29. Clarke R, Leonessa F, Trock B, (2005) Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Seminars in oncology 32: S9-15.
30. Shukla S, Ohnuma S, Ambudkar SV, (2011) Improving cancer chemotherapy with modulators of ABC drug transporters. Current drug targets 12: 621-630.
31. Bark H, Xu HD, Kim SH, Yun J, Choi CH, (2008) P-glycoprotein down-regulates expression of breast cancer resistance protein in a drug-free state. FEBS letters 582: 2595-2600.
32. Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, et al. (2006) Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. British journal of cancer 94: 473-480.
33. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, et al. (1998) Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 4: 1533-1542.